Retrospective, observational study of switching or discontinuing ADHD medication;Retrospectief, observationeel onderzoek naar switchen en stoppen van ADHD-medicatie

Pharmaceutische Weekblad Wetenschappelijk Platform

Volumn 2, Issue 8, 2008, Pages 183-187

  Pauw, R T ^a,b   Dieleman, H G ^a   De Vogel, E M ^a   Eussen, M ^c  

^a ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^b Thans Werkzaam Als Ziekenhuisapotheker   (Netherlands)

^c Opleider Kinder en Jeugdpsychiatrie GGZ de Grote Rivieren Zuid Holland ZuidOost   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE; PIPAMPERONE;

ADOLESCENT; ADULT; AGGRESSION; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CHILD PSYCHIATRY; COMORBIDITY; DEPRESSION; DRUG DOSAGE FORM COMPARISON; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERACTIVITY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTPATIENT CARE; PATIENT COMPLIANCE; PSYCHOPHARMACOTHERAPY; RATING SCALE; RETROSPECTIVE STUDY; SIDE EFFECT; SLEEP DISORDER;

EID: 54549120236     PISSN: 18738982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Taylor E, Döpfner M, Sergeant H, et al. European clinical guidelines for hyperkinetic disorder. First upgrade. Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:I7-30.
2. Barkley RA. Behavioral inhibition, sustained attention and executive functions: constructing a unifying theory of ADHD. Psychological Bull. 1997;121(1):65-94.
3. MTA Cooperative Group. A 14-month randomised clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12):1073-86.
4. Gunning WB. Externaliserende stoornissen; Aandachtstekort-/ hyperactiviteitsstoornissen (ADHD). In: Verheij F, Verhulst FC, Ferdinand RF, red. Kinder-en jeugdpsychiatrie; psychopathologie. Assen: Koninklijke Van Gorcum; 2003. p. 139-51.
5. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameters for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41(2 Suppl.):26S-49S.
6. Remschmidt H, Hoare P, Ettrich C, et al. Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH, results of a 3-week open-label study. Eur Child Adolesc Psychiatry. 2005;14(6):297-304.
7. Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006;15(8):476-95.
8. Gau SS, Chen SJ, Chou WH, et al. National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/ hyperactivity disorder in Taiwan. J Clin Psychiatry. 2008;69(1):131-40.
9. Barkley RA. Attention deficit disorder. A handbook for diagnosis and treatment. New York: Guilford Press; 2005.
10. Coghill D, Spiel G, Baldursson G, et al. ADORE Study Group. Which factors impact on clinician rated impairment of children with ADHD? Eur Child Adolesc Psychiatry. 2006;15(suppl 1):30-7.